This move is archived. Current quotes and coverage live on the stock page.
Follow EPRX
Eupraxia Pharmaceuticals Inc's stock saw a significant boost, closing up over 17% in yesterday's trading session.
Eupraxia Pharmaceuticals Inc (EPRX.TO) experienced a notable increase in its stock price yesterday, closing at CA$10.30, which is a rise of 17.18%. This surge reflects positive market sentiment towards the company's potential in the biotechnology sector.
Investor takeaway: Investors should consider the implications of Eupraxia's recent stock performance, especially given its ongoing developments in biotechnology.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$681.88M
52W high
$13.08
52W low
$7.35
1W change
-11.42%
Beta
1.49
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 58.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+58.3% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$10.32
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
95.1%
Annualized
90-Day Vol
69.3%
Annualized
Trend (90d)
+21.7%
Annualized drift
90d Mean
C$11.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.59 | C$7.63 – C$14.70 |
| 60 trading days | C$10.87 | C$6.83 – C$17.29 |
| 90 trading days | C$11.15 | C$6.32 – C$19.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Eupraxia Pharmaceuticals Inc Market Cap Reaches CA$680.56 Million
With a market cap now exceeding CA$680 million, Eupraxia's valuation highlights its potential to address unmet medical needs in the biotechnology landscape.
Bull case
The recent surge suggests growing investor confidence in Eupraxia's clinical advancements and financial health, particularly after their successful public offerings that raised significant capital.
Bear case
Despite the positive movement, investors should stay cautious as the biotechnology sector can be volatile. Eupraxia's future performance will heavily depend on the outcomes of clinical trials and market conditions.
Advertisement
Market Reaction to Eupraxia's Performance
Eupraxia's stock performance yesterday clearly indicated investor enthusiasm. The company's recent public offerings, which raised considerable capital, likely contributed to this positive sentiment. As the market reacts to Eupraxia's advancements, it's crucial for investors to keep a close eye on ongoing developments. For more insights on the stock, visit our EPRX.TO page.
Future Prospects and Considerations
While the surge in Eupraxia's stock price is encouraging, investors should remain vigilant. The biotechnology sector is full of uncertainties, and Eupraxia's success will largely depend on the results of their clinical trials and the overall market environment. For detailed financial performance, check out our analysis on EPRX.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
